“Efficacy and Tolerability of Valganciclovir 6 Months vs 6 Weeks in Symptomatic Cytomegalovirus Infection in Infants: An Open Level Randomized Controlled Trial”, CLINICMED, vol. 3, no. 1, pp. 18–25, Jan. 2022, doi: 10.24018/clinicmed.2022.3.1.122.